Miao Lan-Fang, Sun Yuan-Yuan, Du Xian-Juan, Xu Nan, Shen Jing-Wei, Hua Hui, Guo Mei, Yang Hai-Jun, Li Jun-Kuo, Zhu Lei
Department of Pathology, Anyang Tumor Hospital, Anyang 455000, Henan Province, China.
Department of Pathology, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang 455000, Henan Province, China.
World J Gastrointest Oncol. 2025 May 15;17(5):105604. doi: 10.4251/wjgo.v17.i5.105604.
Differential diagnosis among atypical hyperplasia (AH) (including reparative hyperplasia and intestinal metaplasia), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and adenocarcinoma (AC) in gastric mucosal biopsies is challenging due to histomorphological overlaps, variability in pathological diagnosis consistency, and limited reproducibility.
To evaluate the diagnostic utility of P53, Ki67, P504S, and IMP3 in gastric cancer and its precancerous lesions, focusing on their effectiveness in distinguishing AH, LGD, HGD, and AC.
From January 2018 to September 2020, a total of 185 gastric mucosal biopsy specimens were analyzed according to the pathological diagnostic criteria outlined in the World Health Organization Classification of Digestive System Tumors (2019). The specimens were categorized into four groups: AH, LGD, HGD, and AC. Immunohistochemistry was employed to assess the expression status of P53, Ki67, P504S, and IMP3. Intergroup comparisons were performed using the test or Fisher's exact probability test to compare the differences in immunohistochemical markers across the distinct lesion groups.
The expression rate of P504S was highest in the LGD group (53.3%, 16/30), while IMP3 expression was highest in the AC group (41.9%, 26/62), followed by the HGD group (33.3%). Significant differences in P504S and IMP3 expression levels were observed among the four lesion groups ( < 0.001). Pairwise comparisons revealed statistically significant differences in P504S expression between the AH group and the LGD, HGD, and AC groups ( < 0.001), as well as significant variations in IMP3 expression between the AH group and the HGD and AC groups, and between the LGD group and the HGD and AC groups ( < 0.001). Additionally, significant correlations were found between P504S and the polarity expression pattern of Ki67, and between IMP3 and the mutation expression pattern of P53 ( < 0.001). The combined detection of P504S with Ki67 and IMP3 with P53 increased the diagnostic sensitivity for LGD and HGD/AC, respectively.
P504S is highly expressed in LGD and is associated with the Ki67 "polarity" expression pattern. IMP3 is highly expressed in HGD/AC and is correlated with the mutation expression pattern. The combined detection of P504S with Ki67 and IMP3 with P53 increased the diagnostic sensitivity for LGD and HGD/AC, respectively. The rational use of P504S, Ki67, IMP3, and p53 can help distinguish gastric cancer and precancerous lesions, improving the early cancer diagnosis rate.
由于组织形态学重叠、病理诊断一致性的变异性以及有限的可重复性,胃黏膜活检中不典型增生(AH)(包括修复性增生和肠化生)、低级别异型增生(LGD)、高级别异型增生(HGD)和腺癌(AC)的鉴别诊断具有挑战性。
评估P53、Ki67、P504S和IMP3在胃癌及其癌前病变中的诊断效用,重点关注它们在区分AH、LGD、HGD和AC方面的有效性。
2018年1月至2020年9月,根据世界卫生组织消化系统肿瘤分类(2019年)中概述的病理诊断标准,对总共185份胃黏膜活检标本进行分析。标本分为四组:AH、LGD、HGD和AC。采用免疫组织化学法评估P53、Ki67、P504S和IMP3的表达状态。使用卡方检验或Fisher精确概率检验进行组间比较,以比较不同病变组间免疫组化标志物的差异。
P504S的表达率在LGD组最高(53.3%,16/30),而IMP3的表达在AC组最高(41.9%,26/62),其次是HGD组(33.3%)。在四个病变组中观察到P504S和IMP3表达水平存在显著差异(P<0.001)。两两比较显示,AH组与LGD、HGD和AC组之间P504S表达存在统计学显著差异(P<0.001),AH组与HGD和AC组之间以及LGD组与HGD和AC组之间IMP3表达也存在显著差异(P<0.001)。此外,发现P504S与Ki67的极性表达模式之间以及IMP3与P53的突变表达模式之间存在显著相关性(P<0.001)。P504S与Ki67联合检测以及IMP3与P53联合检测分别提高了对LGD和HGD/AC的诊断敏感性。
P504S在LGD中高表达,并与Ki67的“极性”表达模式相关。IMP3在HGD/AC中高表达,并与P53的突变表达模式相关。P504S与Ki67联合检测以及IMP3与P53联合检测分别提高了对LGD和HGD/AC的诊断敏感性。合理使用P504S、Ki67、IMP3和p53有助于区分胃癌和癌前病变,提高早期癌症诊断率。